Aging Population Trends Will Expand Rare Therapy Markets Despite Risks
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 16 Analysts
Published
04 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$105.36
53.7% undervalued intrinsic discount16 Aug
US$48.82
1Y
41.7%7D
12.7%